AZTA vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AZTA vs MRK: Head-to-Head Comparison
This page compares Azenta, Inc. (AZTA) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.